

# Oklahoma Health Care Authority

## Drug Utilization Review Board

### (DUR Board)

Meeting – May 12, 2021 @ 4:00pm

## Oklahoma Health Care Authority (OHCA) Webinar

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_RctXaWJVRSCLG2uvcRqTyQ](https://zoom.us/webinar/register/WN_RctXaWJVRSCLG2uvcRqTyQ)

After registering, you will receive a confirmation email containing information about joining the webinar.

### **AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

#### **1. Call to Order**

A. Roll Call – Dr. Wilcox

#### **DUR Board Members:**

Dr. Stephen Anderson –  
Dr. Jennifer de los Angeles –  
Ms. Jennifer Boyett –  
Dr. Markita Broyles –  
Dr. Theresa Garton –  
Dr. Megan Hanner –  
Dr. Lynn Mitchell –  
Dr. John Muchmore –  
Dr. Lee Muñoz –  
Dr. James Osborne –

#### **Telephone Conference Participants**

participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference  
participating via Zoom teleconference

#### **Public Access to Meeting via Zoom:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_RctXaWJVRSCLG2uvcRqTyQ](https://zoom.us/webinar/register/WN_RctXaWJVRSCLG2uvcRqTyQ)

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 936 4044 2965

Passcode: 52923318

#### **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting [www.okhca.org/DUR](http://www.okhca.org/DUR) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

#### **2. Public Comment Forum**

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. April 14, 2021 DUR Minutes – Vote
- B. April 14, 2021 DUR Recommendation Memorandum
- C. Correspondence

Items to be presented by Dr. Chandler, Dr. Ha, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/Prenatal Vitamin Utilization Update – See Appendix B**

- A. Pharmacy Helpdesk Activity for April 2021
- B. Medication Coverage Activity for April 2021
- C. Prenatal Vitamin Utilization Update

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Lyumjev™ (Insulin Lispro-aabc) – See Appendix C**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. News
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Amondys 45™ (Casimersen), Viltepso® (Viltolarsen), and Vyondys 53™ (Golodirsen) – See Appendix D**

- A. Introduction
- B. Cost Comparison: Duchenne Muscular Dystrophy (DMD) Exon-Skipping Therapies
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Verquvo™ (Vericiguat) – See Appendix E**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Breyanzi® (Lisocabtagene Maraleucel) – See Appendix F**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. Breyanzi® (Lisocabtagene Maraleucel) Product Summary
- C. Cost Comparison: Chimeric Antigen Receptor (CAR) T-Cell Therapies for Lymphoma
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Cosela™ (Trilaciclib), Gavreto™ (Pralsetinib), Retevmo® (Selpercatinib), Tabrecta™ (Capmatinib), Tepmetko® (Tepotinib), and Zepzelca™ (Lurbinectedin) – See Appendix G**

- A. New U.S. Food and Drug Administration (FDA) Approval(s) and Indication(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**10. Annual Review of Balversa® (Erdafitinib) and 30-Day Notice to Prior Authorize Cabometyx® (Cabozantinib), Fotivda® (Tivozanib), Jelmyto® (Mitomycin), and Padcev® (Enfortumab Vedotin-ejfv) – See Appendix H**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Balversa® (Erdafitinib)
- D. Prior Authorization of Balversa® (Erdafitinib)

- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**11. Annual Review of Bladder Control Medications and 30-Day Notice to Prior Authorize Gemtesa® (Vibegron) – See Appendix I**

- A. Current Prior Authorization Criteria
- B. Utilization of Bladder Control Medications
- C. Prior Authorization of Bladder Control Medications
- D. Market News and Updates
- E. Gemtesa® (Vibegron) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Bladder Control Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**12. Annual Review of Topical Acne and Rosacea Products and 30-Day Notice to Prior Authorize Zilxi® (Minocycline 1.5% Topical Foam) – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Acne and Rosacea Products
- C. Prior Authorization of Topical Acne and Rosacea Products
- D. Market News and Updates
- E. Zilxi® (Minocycline 1.5% Topical Foam) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Topical Acne and Rosacea Products

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**13. Annual Review of Various Systemic Antibiotics and 30-Day to PA Fetroja® (Cefiderocol) and Kimyrsa™ (Oritavancin) – See Appendix K**

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotics
- C. Prior Authorization of Various Systemic Antibiotics
- D. Market News and Updates
- E. Fetroja® (Cefiderocol) Product Summary
- F. Kimyrsa™ (Oritavancin) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Various Systemic Antibiotics

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**14. Annual Review of Parkinson's Disease (PD) Medications and 30-Day Notice to Prior Authorize Kynmobi™ (Apomorphine) and Ongentys® (Opicapone) – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of PD Medications
- C. Prior Authorization of PD Medications
- D. Market News and Updates
- E. Kynmobi™ (Apomorphine) Product Summary
- F. Ongentys® (Opicapone) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of PD Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**15. Annual Review of Alzheimer's Disease Medications – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer's Disease Medications

- C. Prior Authorization of Alzheimer's Disease Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Alzheimer's Disease Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**16. Annual Review of Allergen Immunotherapies – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Allergen Immunotherapies
- C. Prior Authorization of Allergen Immunotherapies
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**18. Future Business\* (Upcoming Product and Class Reviews)**

- A. Annual Review of the SoonerCare Pharmacy Benefit
- B. Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications
- C. Atypical Antipsychotic Medications
- D. Ophthalmic Anti-Inflammatories
- E. Various Special Formulations

*\*Future product and class reviews subject to change.*

**19. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.